Matthew A. Marx

4.6k total citations
40 papers, 632 citations indexed

About

Matthew A. Marx is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Matthew A. Marx has authored 40 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Matthew A. Marx's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Chemical Synthesis and Analysis (7 papers) and Cancer-related gene regulation (5 papers). Matthew A. Marx is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Chemical Synthesis and Analysis (7 papers) and Cancer-related gene regulation (5 papers). Matthew A. Marx collaborates with scholars based in United States, Germany and Australia. Matthew A. Marx's co-authors include Paul A. Bartlett, Anne‐Laure Grillot, Leo S. Geraci, Matthias Schneider, Thomas A. Kirkland, John Colucci, Stephen F. Martin, Jonathan L. Doty, Beth Cooper and Michael J. Munchhof and has published in prestigious journals such as Journal of the American Chemical Society, PLoS ONE and Cancer Research.

In The Last Decade

Matthew A. Marx

37 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew A. Marx United States 13 378 342 66 41 31 40 632
Jean-Christophe Harmange United States 18 209 0.6× 392 1.1× 60 0.9× 45 1.1× 58 1.9× 24 707
Anne Mengel Germany 12 623 1.6× 414 1.2× 88 1.3× 58 1.4× 27 0.9× 18 967
Michaël Prakesch Canada 15 324 0.9× 287 0.8× 64 1.0× 48 1.2× 13 0.4× 25 609
Jayoung Song South Korea 16 269 0.7× 414 1.2× 125 1.9× 42 1.0× 28 0.9× 34 723
David J. Richard United States 18 419 1.1× 500 1.5× 37 0.6× 61 1.5× 36 1.2× 24 838
Viswanath Arutla India 15 571 1.5× 265 0.8× 57 0.9× 65 1.6× 12 0.4× 27 774
Yong‐Cheng Ma China 13 344 0.9× 275 0.8× 53 0.8× 40 1.0× 28 0.9× 19 630
Sébastien L. Degorce United Kingdom 13 232 0.6× 265 0.8× 100 1.5× 31 0.8× 15 0.5× 26 505
Heba A. Hassan Egypt 14 387 1.0× 261 0.8× 94 1.4× 36 0.9× 43 1.4× 31 595
Peter Sheldrake United Kingdom 17 530 1.4× 322 0.9× 85 1.3× 67 1.6× 10 0.3× 41 856

Countries citing papers authored by Matthew A. Marx

Since Specialization
Citations

This map shows the geographic impact of Matthew A. Marx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Marx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Marx more than expected).

Fields of papers citing papers by Matthew A. Marx

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Marx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Marx. The network helps show where Matthew A. Marx may publish in the future.

Co-authorship network of co-authors of Matthew A. Marx

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Marx. A scholar is included among the top collaborators of Matthew A. Marx based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Marx. Matthew A. Marx is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daemen, Anneleen, Natalie Yuen, Aleksandr Pankov, et al.. (2024). Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models. Cancer Research. 84(6_Supplement). 6586–6586. 3 indexed citations
2.
Smith, Christopher R., et al.. (2024). Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery Program. The Journal of Organic Chemistry. 89(6). 3875–3882. 4 indexed citations
3.
Rahbæk, Lisa, Cornelius Cilliers, Christopher J. Wegerski, et al.. (2024). Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor. Cancer Chemotherapy and Pharmacology. 95(1). 7–7. 2 indexed citations
4.
Smith, Christopher R., Ruth Aranda, James G. Christensen, et al.. (2022). Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors. Bioorganic & Medicinal Chemistry. 71. 116947–116947. 8 indexed citations
5.
Smith, Christopher R., Svitlana Kulyk, Lars D. Engstrom, et al.. (2021). Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors. Cancer Research. 81(13_Supplement). LB003–LB003. 10 indexed citations
6.
7.
Christensen, James G., Jay B. Fell, Jill Hallin, et al.. (2019). Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers. Molecular Cancer Therapeutics. 18(12_Supplement). C069–C069. 5 indexed citations
8.
Martínez, Ricardo, Alessandra Blasina, Jill Hallin, et al.. (2015). Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS ONE. 10(9). e0138616–e0138616. 29 indexed citations
9.
Marx, Matthew A.. (2014). Social History Matters–The Impact of Illicit Drug Use on tPA Use and In-Hospital Mortality in Acute Ischemic Stroke. International Neuropsychiatric Disease Journal. 2(3). 127–135. 3 indexed citations
10.
Cheng, Hengmiao, Chunze Li, Simon Bailey, et al.. (2012). Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Medicinal Chemistry Letters. 4(1). 91–97. 59 indexed citations
11.
Kinross, Kathryn M., Daniel V. Brown, Carleen Cullinane, et al.. (2010). Abstract 3484: In vivo activity of combined PI3k/mTOR and MEK-inhibition in a K-RASG12D; PTEN deletion mouse model of ovarian cancer. Cancer Research. 70(8_Supplement). 3484–3484. 1 indexed citations
12.
Yuan, Jing, Adam Pavlı́c̀ek, Keith A. Ching, et al.. (2010). Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and negative segments. Cancer Research. 70(8_Supplement). LB–302. 1 indexed citations
13.
Cherney, Robert J., John Colucci, Christine Courillon, et al.. (2003). Total Synthesis of (+)‐Ambruticin S.. ChemInform. 34(51). 1 indexed citations
14.
Munchhof, Michael J., Jean S. Beebe, Beth Cooper, et al.. (2003). Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. Bioorganic & Medicinal Chemistry Letters. 14(1). 21–24. 86 indexed citations
15.
Erdlenbruch, Bernhard, Verena Jendrossek, Matthew A. Marx, et al.. (1998). Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo.. PubMed. 18(4A). 2551–7. 31 indexed citations
16.
17.
Marx, Matthew A., et al.. (1997). Synthetic Design for Combinatorial Chemistry. Solution and Polymer-Supported Synthesis of Polycyclic Lactams by Intramolecular Cyclization of Azomethine Ylides. Journal of the American Chemical Society. 119(26). 6153–6167. 66 indexed citations
18.
Bartlett, Paul A., et al.. (1994). Divergence between the enzyme-catalyzed and noncatalyzed synthesis of 3-dehydroquinate. The Journal of Organic Chemistry. 59(8). 2082–2085. 16 indexed citations
19.
Pyerin, Walter, Matthew A. Marx, & Hiroyuki Taniguchi. (1986). Phosphorylation of microsome-bound cytochrome P-450 LM2. Biochemical and Biophysical Research Communications. 134(2). 461–468. 21 indexed citations
20.
Schabort, J.C., et al.. (1978). The excreted β-cyclopiazonate oxidocyclase isoenzymes from Penicillium cyclopium—II. Peptide mapping studies. International Journal of Biochemistry. 9(6). 437–438. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean-Christophe Harmange Breakdown of academic impact, for papers by Anne Mengel Breakdown of academic impact, for papers by Michaël Prakesch Breakdown of academic impact, for papers by Jayoung Song Breakdown of academic impact, for papers by David J. Richard Breakdown of academic impact, for papers by Viswanath Arutla Breakdown of academic impact, for papers by Yong‐Cheng Ma Breakdown of academic impact, for papers by Sébastien L. Degorce Breakdown of academic impact, for papers by Heba A. Hassan Breakdown of academic impact, for papers by Peter Sheldrake
Rankless by CCL
2026